Byrd JC - Search Results

1

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.

Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC. Alinari L, et al. Among authors: byrd jc. Oncogene. 2007 May 28;26(25):3644-53. doi: 10.1038/sj.onc.1210380. Oncogene. 2007. PMID: 17530018 Review.

2

Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals.

Byrd JC, Rai KR, Sausville EA, Grever MR. Byrd JC, et al. Semin Oncol. 1998 Feb;25(1):65-74. Semin Oncol. 1998. PMID: 9482528 Review.

3

Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.

Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville E, Grever MR. Byrd JC, et al. Blood. 1998 Nov 15;92(10):3804-16. Blood. 1998. PMID: 9808574 Free article.

4

Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.

Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR. Byrd JC, et al. Blood. 1999 Aug 15;94(4):1401-8. Blood. 1999. PMID: 10438728 Free article.

5

Update on the biology of chronic lymphocytic leukemia.

Bannerji R, Byrd JC. Bannerji R, et al. Among authors: byrd jc. Curr Opin Oncol. 2000 Jan;12(1):22-9. doi: 10.1097/00001622-200001000-00004. Curr Opin Oncol. 2000. PMID: 10687725 Review.

6

Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.

Waselenko JK, Grever MR, Beer M, Lucas MA, Byrd JC. Waselenko JK, et al. Among authors: byrd jc. Semin Oncol. 2000 Apr;27(2 Suppl 5):44-51. Semin Oncol. 2000. PMID: 10877052 Review.

7

Novel therapies for chronic lymphocytic leukemia in the 21st century.

Byrd JC, Waselenko JK, Keating M, Rai K, Grever MR. Byrd JC, et al. Semin Oncol. 2000 Oct;27(5):587-97. Semin Oncol. 2000. PMID: 11049025 Review.

8

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW. Byrd JC, et al. J Clin Oncol. 2001 Apr 15;19(8):2153-64. doi: 10.1200/JCO.2001.19.8.2153. J Clin Oncol. 2001. PMID: 11304767 Clinical Trial.

9

Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia.

Waselenko JK, Grever MR, Shinn CA, Flinn IW, Byrd JC. Waselenko JK, et al. Among authors: byrd jc. Leuk Res. 2001 Jun;25(6):435-40. doi: 10.1016/s0145-2126(00)00106-5. Leuk Res. 2001. PMID: 11337014

10

Antibody therapy of acute and chronic leukemias.

Cataland SR, Lucas M, Byrd JC. Cataland SR, et al. Among authors: byrd jc. Curr Pharm Biotechnol. 2001 Dec;2(4):357-67. doi: 10.2174/1389201013378608. Curr Pharm Biotechnol. 2001. PMID: 11762417 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

861 results

Search Page

Filters